Annals of Oncology

Article	Citations
195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis	1609
285P Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial	1330
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database	1163
178P Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of obser	902
476P How to predict microsatellite instability (MSI) status in locally advanced gastric cancer? A preoperative CT-based proposal	774
19P Adjuvant chemotherapy in colon cancer: 6 months better than 3?	680
215P Peptide receptor radionuclide therapy versus capecitabine/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors	650
225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors	638
468P Association of prior and concurrent malignancies with overall survival in a large European single-center gastroesophageal cancer cohort	604
459P Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity	556
133P The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)	552
45P Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis	450
Identifying genetic loci associated with an increased risk for early-onset colorectal cancer	426
13P Genomic signatures of recurrence after resection of node-negative colorectal cancer	425
Table of Contents	410
386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)	396
CN100 Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study	387
28P Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy	382
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy	336
897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma	328
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part	316
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies	313
1768P Desmoid tumors: Experience of a Spanish reference center	299
1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC	299
1270P Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial	270

2007P Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials	241
87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making	240
199P Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival	237
913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer	230
CN107 The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study	222
1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma	213
568P Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort	211
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study	208
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)	200
473P A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)	197
1493P The Italian version of the FAMCARE-P13 questionnaire: A validation study	193
1992P Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (N	188
2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (c	184
1385P Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma	182
CN11 The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus	180
495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junct	177
Imatinib’s last lessons? A roadmap to cure	177
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)	175
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country	172
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer	172
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma	172
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE	168
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway	160
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre	159
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India	158
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study	156
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling	150
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction	144
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study	142
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor	139
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals	134
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC	134
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China	132
231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin	124
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care	124
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%	122
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes	121
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study	121
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported	120
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma	119
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer	118
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era	117
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report	117
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia	115
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis	114
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience	114
1242MO The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: A randomized controlled, open-label phase II study	113
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study	113
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients	113
1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling	112

Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment	109
CN14 Cancer prevention awareness among Croatian AYA population	108
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)	108
82P Obtaining microvesicles from T-lymphocytes using various methods of induction	107
332P Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study	105
166P Metabolomic prediction of breast cancer treatment toxicities	105
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes	103
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi	101
2335P Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma	101
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study	100
1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)	96
1O CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites	94
2092P Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors	93
14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy	93
1905P Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma	93
1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)	92
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study	92
1601P Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy	91
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype	91
2067P Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data	90
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma	90
CN69 Experiences of patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A qualitative study	87
809P Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship	87
1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin	85
CN55 The impact of psychosocial support on the overall health of cancer patients in the COVID-19 era	85
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial	84
1608P Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy	84
2173P Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital	83
515P A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients	83
1232P Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification	82
577P Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer	82
578P Tissue-resident microbiota characterization in colorectal cancer metastases	82
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)	81
1921MO Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)	80
2132P Unmet needs, quality of life, and financial toxicity in survivors of lung cancer	79
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer	79
1997P A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer	79
56P SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume	77
1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients	77
457P Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting	77
365P Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis	76
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary	76
1651P Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy	76
1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands	75
1677P Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma	75
2272P Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)	74
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?	74
1681P A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer	73
1593MO Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China	73
49P Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer	73
22P Clinical significance of DNA damage response mutations in early stage NSCLC	73
121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium	72
MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review	72
1702P Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022	71
2116P Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea	71
936P Triple oral metronomic chemotherapy (OMCT) versus physician choice chemotherapy after failure of platinum-based therapy in advanced head and neck squamous cell cancer (HNSCC): A phase III randomi	70
971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China	70
907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II	70
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5	69
2276P Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer	69
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial	68
1707P Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology	68
1673P Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study	66
995P Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada	64
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma	64
2293P Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers	64
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy	64
622P A prognostic and immune infiltration analysis of CCL26 in pan-cancer	63
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small ce	63
113P Molecular profiling of biliary tract cancers in patients of African and European ancestries	62
243P Targeting autophagy in tumor-associated macrophages effects the phenotype and tumor progression in urothelial carcinoma of bladder	62
430P Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries	62
213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastati	62
195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis	62
1274P Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer	62
414P Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis	61
34P Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer	61
2285P Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls	60
331MO Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus	60
375P Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital	59

451P The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia	59
268P Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study	59
398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure	58
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India	58
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies	57
P-85 Treatment propensity and the feasibility of cisplatin plus gemcitabine in elderly patients aged ≥ 75 years with biliary tract cancer	57
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience	57
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data	57
MO36-5 Non-familial prospective risk factors in predicting cancer of unknown primary: A systematic review and meta-analysis	56
JS01-3 Optimizing cancer genome medicine in clinical practice in Japan	56
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study	56
350P Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research	56
MO6-5 Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma	55
1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration	55
LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, op	55
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)	54
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study	54
LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positi	54
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)	54
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy	54
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study	53
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization	52
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation	52
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1	52
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy	52
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)	51
1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study	51
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)	51
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients	51
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India	51
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience	51
85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXI	51
37P Development of splice switching antisense oligonucleotides targeting midkine	50
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data	50
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence	50
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis	49
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis	49
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry	49
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the	49
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito	49
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients	49
1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France	48
LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in	48
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria	48
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study	48
1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)	48
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data	47
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort	47
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene	47
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome	47
MO1-6 Steroid-resistant and refractory irAEs requiring additional immunosuppressants to steroids in advanced NSCLC patients	47
MO20-3 Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study	46
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis	46
1863P Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia	45
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study	45
574P First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study	44
1182P Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform	44
211P GynePDX: A new platform of preclinical models for endometrial and ovarian cancers	44
761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies	44
978P Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective,	44
1093P Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma	44
256P Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer	44
1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age	43
1748P A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)	43
1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma	43
138P Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics	43
1632P Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial	43
557P Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals	43
727P Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China	43
229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies	42
MO42-5 A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study)	42
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with adva	42
1747P Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study	42
SY19-5 Utility of circulating tumor DNA-based MRD monitoring following allogeneic transplantation in adult acute lymphoblastic leukemia	42
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer	41
MO47-4 Neutrophil-lymphocyte ratio predicts prognosis in bone metastasis: meta-analysis of retrospective studies	41
MO5-1 Efficacy and safety of olaparib as a potential treatment for patients with pancreatic cancer: a systematic review	41
MO29-5 Correlation of COVID-19 pandemic and medical seeking behaviour in breast cancer patients at Siloam Hospitals Lippo Village	41
P11-9 Association of Charlson Comorbidity Index and safety of endoscopic resection gastric cancer patients: systematic review	41
MO32-5 Impact of patient travel costs on disparities in precision oncology clinical trials	41
P38-2 Efficacy and safety of lazertinib in the treatment of EGFR-mutated non-small cell lung cancer: a systematic review	40
787P First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors	40
60P A phase II trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report	40
SY24-KL1 Perioperative chemotherapy for gastric and gastroesophageal junction cancer, European perspective	40
Is adjuvant ribociclib ready for prime time?	40
850MO Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A tria	40
283P Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study	40
1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)	40
P18-3 Effect of pembrolizumab for elderly head and neck cancer by CPS status: subanalysis of a multicenter retrospective study	39
P70-5 Outcomes of pancreatic cancer patients treated with Nal-IRI after first-line mFOLFIRINOX or nab-paclitaxel/gemcitabine	39
MO22-2 Challenges in introducing an unsupervised exercise program for cancer patients during and after treatment	39
P79-7 Efficacy of PTX+RAM and nab-PTX+RAM for advanced gastric cancer with and without peritoneal dissemination	39
972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial	39
SY7-4 The role of anti-angiogenic therapy in tumor immunity	39
P19-5 Potential of ACTL6A and ERCC1 gene for cisplatin resistance among locally advanced head and neck cancer patients	39